Provided by Tiger Trade Technology Pte. Ltd.

Oramed Pharmaceuticals

4.81
0.0000
Volume:65.59K
Turnover:315.35K
Market Cap:200.08M
PE:1.16
High:4.86
Open:4.81
Low:4.74
Close:4.81
52wk High:5.19
52wk Low:2.09
Shares:41.60M
Float Shares:31.77M
Volume Ratio:0.34
T/O Rate:0.21%
Dividend:0.25
Dividend Rate:5.20%
EPS(TTM):4.15
EPS(LYR):1.50
ROE:74.24%
ROA:-3.42%
PB:0.63
PE(LYR):3.21

Loading ...

Company Profile

Company Name:
Oramed Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2002
Employees:
4
Office Location:
1185 Avenue of the Americas,Third Floor,New York,New York,United States
Zip Code:
10036
Fax:
- -
Introduction:
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Directors

Name
Position
Nadav Kidron
President, Chief Executive Officer and Chairman
Arie Mayer
Independent Director
Benjamin Shapiro
Independent Director
Daniel Aghion
Independent Director
Miriam Kidron
Chief Scientific Officer and Director
Yehuda Reznick
Independent Director

Shareholders

Name
Position
Nadav Kidron
President, Chief Executive Officer and Chairman
Joshua Hexter
Chief Operating and Business Officer
Miriam Kidron
Chief Scientific Officer and Director